As DHL Group unveils its full-year 2025 financial results today, the logistics giant is also outlining its strategic roadmap for the future. The supervisory board’s decision to extend CEO Tobias Meyer’s contract ahead of schedule underscores a commitment to continuity in executing the ambitious “Strategy 2030.” Market participants are keenly assessing the company’s performance amidst a volatile air freight rate environment.
Jefferies Sees Upside, Dividend in Focus
The current share price, trading between 47 and 48 euros, is viewed by some analysts as an attractive entry point. U.S. investment bank Jefferies reaffirmed its “Buy” rating on Tuesday, maintaining a price target of 60 euros and highlighting significant potential upside. Investors are also awaiting the dividend proposal for the past fiscal year. Market experts, on average, anticipate a modest increase in the payout to 1.87 euros per share.
Today’s financial release provides the foundation for evaluating the current business cycle. Particular attention will be paid to management’s guidance for the 2026 operating profit and further details on scaling its healthcare initiatives.
Operational Resilience and Innovative Logistics
Operationally, the group has demonstrated recent strength. For the third quarter of 2025, earnings before interest and taxes (EBIT) climbed to 1.5 billion euros. This improvement occurred despite a slight currency-driven dip in revenue, which settled at 20.1 billion euros.
To boost efficiency on key trade lanes, the company began testing a novel hybrid “Truck-Air-Logistics” model in January. This approach between China and Europe is designed to enhance flexibility and responsiveness to fluctuations within global supply chains.
A Billion-Euro Bet on Healthcare Logistics
A central pillar of DHL’s long-term growth strategy is the deliberate expansion of its “DHL Health Logistics” division. The company plans to invest two billion euros into this high-margin sector by 2030. The capital will fund the expansion of specialized pharmaceutical hubs and temperature-controlled supply chains for sensitive products. Management aims to generate five billion euros in additional annual revenue from this segment by the end of the decade.
These investments have a global footprint: half of the allocated funds are destined for the Americas region, with 25 percent each flowing into the Asia-Pacific and EMEA (Europe, Middle East, Africa) areas. The Life Sciences and Healthcare unit already established a strong foundation, reporting global revenue of approximately five billion euros in 2024.